Abstract:Nipah virus (NiV) disease is a bat-borne zoonosis responsible for outbreaks with high lethality and is a priority for vaccine development. With funding from the Coalition of Epidemic Preparedness Innovations (CEPI), we are developing a chimeric vaccine (PHV02) composed of recombinant vesicular stomatitis virus (VSV) expressing the envelope glycoproteins of both Ebola virus (EBOV) and NiV. The EBOV glycoprotein (GP) mediates fusion and viral entry and the NiV attachment glycoprotein (G) is a ligand for cell receptors, and stimulates neutralizing antibody, the putative mediator of protection against NiV. PHV02 is identical in construction to the registered Ebola vaccine (Ervebo) with the addition of the NiV G gene. NiV ephrin B2 and B3 receptors are expressed on neural cells and the wild-type NiV is neurotropic and causes encephalitis in affected patients. It was therefore important to assess whether the NiV G alters tropism of the rVSV vector and serves as a virulence factor. PHV02 was fully attenuated in adult hamsters inoculated by the intramuscular (IM) route, whereas parental wild-type VSV was 100% lethal. Two rodent models (mice, hamsters) were infected by the intracerebral (IC) route with graded doses of PHV02. Comparator active controls in various experiments included rVSV-EBOV (representative of Ebola vaccine) and yellow fever (YF) 17DD commercial vaccine. These studies showed PHV02 to be more neurovirulent than both rVSV-EBOV and YF 17DD in infant animals. PHV02 was lethal for adult hamsters inoculated IC but not for adult mice. In contrast YF 17DD retained virulence for adult mice inoculated IC but was not virulent for adult hamsters. Because of the inconsistency of neurovirulence patterns in the rodent models, a monkey neurovirulence test (MNVT) was performed, using YF 17DD as the active comparator because it has a well-established profile of quantifiable microscopic changes in brain centers and a known reporting rate of neurotropic adverse events in humans. In the MNVT PHV02 was significantly less neurovirulent than the YF 17DD vaccine reference control, indicating that the vaccine will have an acceptable safety profile for humans. The findings are important because they illustrate the complexities of phenotypic assessment of novel viral vectors with tissue tropisms determined by transgenic proteins, and because it is unprecedented to use a heterologous comparator virus (YF vaccine) in a regulatory-enabling study. This approach may have value in future studies of other novel viral vectors. Nipah virus (NiV) disease is a highly lethal bat-borne virus with epidemic potential causing inflammation of the brain and a severe respiratory syndrome and is a high priority for vaccine development. We developed a novel single-dose vaccine that protects animals against disease and death caused by NiV and have started clinical trials. The vaccine is a live, recombinant vesicular stomatitis virus (VSV) vector identical to the recently approved Ebola vaccine (Ervebo) but also expressing the NiV G protein responsible for attachment of the virus to cell receptors. Vaccination results in antibodies to the G protein that block entry of the virus into cells. Since addition of the NiV receptor-binding G protein to a live virus could potentially target it to receptors on brain cells, extensive safety tests for neurovirulence were required involving direct inoculation of the vaccine virus into brains of different animal models. We showed that the vaccine candidate was significantly less neurovirulent in non-human primates than an unrelated approved live viral vaccine against yellow fever which has a long record of safe use and a known incidence of rare neurological adverse events. The use of an unrelated vaccine as a comparator is unprecedented in regulatory science and provides a novel approach to safety testing that may be applicable to other vaccines.

Optimization of Bangladesh and Malaysian genotype recombinant reporter Nipah viruses for in vitro antiviral screening and in vivo disease modeling

Development of Fusion-Based Assay as a Drug Screening Platform for Nipah Virus Utilizing Baculovirus Expression Vector System

Establishment of a novel minigenome system for the identification of drugs targeting Nipah virus replication

Development of a novel real-time polymerase chain reaction assay for the quantitative detection of Nipah virus replicative viral RNA

A Novel Transcription and Replication-Competent Virus-Like Particles System Modelling the Nipah Virus Life Cycle

Revolutionizing Nipah virus vaccinology: insights into subunit vaccine development strategies and immunological advances

Streamlined detection of Nipah virus antibodies using a split NanoLuc biosensor

Nipah Virus: A Multidimensional Update

Protracted molecular dynamics and secondary structure introspection to identify dual-target inhibitors of Nipah virus exerting approved small molecules repurposing

A systematic review on Nipah virus: global molecular epidemiology and medical countermeasures development

Evaluation of the immunogenicity of an mRNA vectored Nipah virus vaccine candidate in pigs

Emergence and Adaptive Evolution of Nipah Virus.

Nipah Virus: An Overview of the Current Status of Diagnostics and Their Role in Preparedness in Endemic Countries

Antiviral Activity, Pharmacoinformatics, Molecular Docking, and Dynamics Studies of Azadirachta indica Against Nipah Virus by Targeting Envelope Glycoprotein: Emerging Strategies for Developing Antiviral Treatment

Novel Nipah virus immune-antagonism strategy revealed by experimental and computational study.

Recombinant vesicular stomatitis vaccine against nipah virus has a favorable safety profile: Model for assessment of live vaccines with neurotropic potential

Therapeutic administration of a cross-reactive mAb targeting the fusion glycoprotein of Nipah virus protects nonhuman primates

Nipah Virus Therapeutics: A Systematic Review to Support Prioritisation for Clinical Trials

Rabies-based vaccine induces potent immune responses against Nipah virus

Are we ready to fight the Nipah virus pandemic? An overview of drug targets, current medications, and potential leads

Updated Insights into the Phylogenetics, Phylodynamics, and Genetic Diversity of Nipah Virus (NiV)